Skip to content

Homoeopathic medicine Abroma augusta in Diabetes mellitus

Role of Homoeopathic Medicine Abroma augusta in the management of Type-II Diabetes Mellitus: A Pretest-Posttest Interventional Pilot Trial - Nil

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057490
Enrollment
20
Registered
2023-09-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Abroma augusta: Aborma augusta is a known and safe homoeopathic medicine for therapeutic use. The medicine will be administered orally. Potency, doses and repetition will be as per homo

Sponsors

National Institute of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age: 18 - 65 years. ii. Gender: Both Male and Female. iii. Patient with fasting blood sugar level more than 126 mg/dl. iv. Patient with post-prandial blood sugar level more than 200 mg/dl. v. Patients taking anti-diabetic drugs will continue with same dose-schedule throughout the study. vi. After case taking the totality of symptom of the patient should be indicated to that of drug Abroma augusta. vii. Patient voluntarily giving written informed consent for the study.

Exclusion criteria

Exclusion criteria: Uncontrolled diabetes mellitus and severe co-morbidities or any other uncontrolled systemic diseases, life-threatening illness etc. affecting Quality of Life. ii. Pregnant or breast-feeding women. iii. Substance abuse and/ or dependence. iv. Psychologically unstable patients. v. Self-reported immune-compromised state. vi. Under-going homoeopathic treatment for any chronic diseases for last 3 months. vii. Patients who are unable to read the patient information sheet and written consent form. viii. Patient unwilling to take part in the study and not giving written consent for this study.

Design outcomes

Primary

MeasureTime frame
To evaluate the changes in the fasting and post-prandial blood sugar level.Timepoint: Baseline and after 3 months.

Secondary

MeasureTime frame
Measure Yourself Medical Outcome Profile-2 (MYMOP-2)Timepoint: Baseline and after 3 months.

Countries

India

Contacts

Public ContactDr Rajib Purkait

National Institute od Homoeopathy

drspaul.2007@gmail.com9830148968

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026